These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 29550045)
1. Impact of ticagrelor and aspirin versus clopidogrel and aspirin in symptomatic patients with peripheral arterial disease: Thrombus burden assessed by optical coherence tomography. Yang X; Leesar MA; Ahmed H; Lendel V; Rodriguez G; Mutlu D; Cawich I; Prasad A; Oglesby M; Marmagkiolis K; Phillips NE; Jouke D; Michalek J; Liu Q; Milner T; McElroy A; Hoyt T; Feldman MD; Cilingiroglu M Cardiovasc Revasc Med; 2018 Oct; 19(7 Pt A):778-784. PubMed ID: 29550045 [TBL] [Abstract][Full Text] [Related]
2. Effect of P2Y Spinthakis N; Farag M; Gue YX; Srinivasan M; Wellsted DM; Gorog DA Thromb Res; 2019 Jan; 173():102-108. PubMed ID: 30500673 [TBL] [Abstract][Full Text] [Related]
3. Ticagrelor versus clopidogrel for prevention of subclinical stent thrombosis detected by optical coherence tomography in patients with drug-eluting stent implantation-a multicenter and randomized study. Wu X; You W; Wu Z; Wu Q; Jiang J; Yan H; Ye F; Chen S Platelets; 2021 Apr; 32(3):404-412. PubMed ID: 32326796 [No Abstract] [Full Text] [Related]
4. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. Berger JS; Abramson BL; Lopes RD; Heizer G; Rockhold FW; Baumgartner I; Fowkes FGR; Held P; Katona BG; Norgren L; Jones WS; Millegård M; Blomster J; Reist C; Hiatt WR; Patel MR; Mahaffey KW Vasc Med; 2018 Dec; 23(6):523-530. PubMed ID: 29992857 [TBL] [Abstract][Full Text] [Related]
5. Antiplatelet effects of ticagrelor versus clopidogrel after coronary artery bypass graft surgery: A single-center randomized controlled trial. Xu F; Feng W; Zhou Z; Zhang Y; Diao X; Hu S; Zheng Z J Thorac Cardiovasc Surg; 2019 Aug; 158(2):430-437.e4. PubMed ID: 30501950 [TBL] [Abstract][Full Text] [Related]
6. Ticagrelor Versus Clopidogrel in Patients with Late or Very Late Stent Thrombosis. Zhou J; Tan Y; Liu C; Zhou P; Sheng Z; Li J; Chen R; Zhao H; Song L; Yan H Cardiovasc Drugs Ther; 2020 Oct; 34(5):677-684. PubMed ID: 32572652 [TBL] [Abstract][Full Text] [Related]
7. Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction. Di Vito L; Versaci F; Limbruno U; Pawlowski T; Gatto L; Romagnoli E; Cattabiani MA; Micari A; Trivisonno A; Marco V; Prati F J Cardiovasc Med (Hagerstown); 2016 Sep; 17(9):701-6. PubMed ID: 27467458 [TBL] [Abstract][Full Text] [Related]
8. Platelet Inhibition with Ticagrelor versus Clopidogrel in Diabetic Patients after Percutaneous Coronary Intervention for Chronic Coronary Syndromes. Liu Z; Tian R; Wang Y; Chen Q; Li J; Xu L; Zhang S Thromb Haemost; 2020 Aug; 120(8):1221-1229. PubMed ID: 32668483 [TBL] [Abstract][Full Text] [Related]
9. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. Hiatt WR; Fowkes FG; Heizer G; Berger JS; Baumgartner I; Held P; Katona BG; Mahaffey KW; Norgren L; Jones WS; Blomster J; Millegård M; Reist C; Patel MR; N Engl J Med; 2017 Jan; 376(1):32-40. PubMed ID: 27959717 [TBL] [Abstract][Full Text] [Related]
10. DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan. Chen YC; Lin FY; Lin YW; Cheng SM; Lin RH; Chuang CL; Sheu JS; Chen SM; Chang CC; Tsai CS Am J Cardiovasc Drugs; 2019 Feb; 19(1):75-86. PubMed ID: 30467686 [TBL] [Abstract][Full Text] [Related]
11. Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention. Xi Z; Zhou Y; Zhao Y; Liu X; Liang J; Chai M; Yu Y; Liu W Cardiovasc Drugs Ther; 2020 Apr; 34(2):179-188. PubMed ID: 32140798 [TBL] [Abstract][Full Text] [Related]
12. Potent effect of prasugrel on acute phase resolution of intra-stent athero-thrombotic burden after percutaneous intervention to acute coronary syndrome. Tsukiyama Y; Kozuki A; Shinke T; Otake H; Kijima Y; Masano T; Nagoshi R; Shibata H; Takeshige R; Yanaka KI; Shite J; Hirata KI J Cardiol; 2018 Nov; 72(5):403-410. PubMed ID: 29731189 [TBL] [Abstract][Full Text] [Related]
13. Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial. Moll F; Baumgartner I; Jaff M; Nwachuku C; Tangelder M; Ansel G; Adams G; Zeller T; Rundback J; Grosso M; Lin M; Mercur MF; Minar E; J Endovasc Ther; 2018 Apr; 25(2):158-168. PubMed ID: 29552984 [TBL] [Abstract][Full Text] [Related]
14. Ticagrelor Does Not Improve Endothelial Dysfunction in Stable Survivors of Acute Coronary Syndrome. Lim S; Choo EH; Kim CJ; Choi IJ; Lee KY; Hwang BH; Lee JM; Chung WS; Chang K J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):442-449. PubMed ID: 31035775 [TBL] [Abstract][Full Text] [Related]
15. Ticagrelor and the Prevention of Microvascular Complications in Diabetes Patients with Lower Extremity Arterial Disease; Rationale and Design of the Hema-Kinesis Trial. Rosenson RS; Chen Q; Najera SD; Lee ML; Cho DJ Cardiovasc Drugs Ther; 2018 Oct; 32(5):443-451. PubMed ID: 30074112 [TBL] [Abstract][Full Text] [Related]
16. A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention. Tangelder MJ; Nwachuku CE; Jaff M; Baumgartner I; Duggal A; Adams G; Ansel G; Grosso M; Mercuri M; Shi M; Minar E; Moll FL J Endovasc Ther; 2015 Apr; 22(2):261-8. PubMed ID: 25809373 [TBL] [Abstract][Full Text] [Related]
17. Effects of ticagrelor on neointimal hyperplasia and endothelial function, compared with clopidogrel and prasugrel, in a porcine coronary stent restenosis model. Kim HK; Jeong MH; Lim KS; Kim JH; Lim HC; Kim MC; Hong YJ; Kim SS; Park KH; Chang KS Int J Cardiol; 2017 Aug; 240():326-331. PubMed ID: 28487152 [TBL] [Abstract][Full Text] [Related]
18. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963 [TBL] [Abstract][Full Text] [Related]
19. Platelet MicroRNA 365-3p Expression Correlates with High On-treatment Platelet Reactivity in Coronary Artery Disease Patients. Chen YC; Lin FY; Lin YW; Cheng SM; Chang CC; Lin RH; Chuang CL; Sheu JS; Chen SM; Tsai CS Cardiovasc Drugs Ther; 2019 Apr; 33(2):129-137. PubMed ID: 30783954 [TBL] [Abstract][Full Text] [Related]
20. Ticagrelor versus clopidogrel in patients undergoing implantation of paclitaxel-eluting stent in the femoropopliteal district: A randomized pilot study using frequency-domain optical coherence tomography. Ducci K; Liistro F; Porto I; Ventoruzzo G; Angioli P; Falsini G; Vergallo R; Bolognese L Int J Cardiol; 2020 Apr; 304():192-197. PubMed ID: 32007230 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]